Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
Open Access
- 1 August 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (3) , 1080-1082
- https://doi.org/10.1182/blood-2007-03-080630
Abstract
To the editor: We read with great interest the recent publication by Kantarjian and colleagues addressing the value of different outpatient low-dose decitabine (DAC) schedules in higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia.[1][1] By the Bayesian design of thatKeywords
This publication has 8 references indexed in Scilit:
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionNew England Journal of Medicine, 2006
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selectionNature Clinical Practice Oncology, 2005
- Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.Blood, 2005
- Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cellsBlood, 2005
- Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineBritish Journal of Haematology, 2001
- Bayesian interim analysis of phase II cancer clinical trialsStatistics in Medicine, 1997
- A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemiaBritish Journal of Haematology, 1992